Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) CFO Scott Ullem sold 7,700 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company's stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Edwards Lifesciences Stock Performance
EW opened at $83.18 on Wednesday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock's 50 day moving average price is $81.19 and its two-hundred day moving average price is $78.88. The firm has a market capitalization of $48.27 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 3.79 and a beta of 0.97. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences's revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.
Institutional Investors Weigh In On Edwards Lifesciences
A number of institutional investors have recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the first quarter valued at $26,000. SouthState Corp acquired a new position in Edwards Lifesciences during the first quarter worth $27,000. Rosenberg Matthew Hamilton acquired a new position in Edwards Lifesciences during the second quarter worth $28,000. Finally, True Wealth Design LLC lifted its holdings in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after acquiring an additional 259 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have issued reports on EW. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 31st. Raymond James Financial upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and set a $96.00 target price for the company in a research note on Monday, November 3rd. Barclays reissued an "overweight" rating and set a $103.00 target price (up from $99.00) on shares of Edwards Lifesciences in a research report on Monday. Oppenheimer cut Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a "neutral" rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $93.09.
Get Our Latest Research Report on Edwards Lifesciences
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
